Expression of transient receptor potential canonical 1 (TRPC1) in tongue squamous cell carcinoma and correlations with clinicopathological features and outcomes.

Expression of transient receptor potential canonical 1 (TRPC1) in tongue squamous cell carcinoma and correlations with clinicopathological features and outcomes.
复制标题

舌鳞状细胞癌中瞬时受体电位规范 1 (TRPC1) 的表达及其与临床病理特征和结果的相关性。

DOI:
--
复制
发表时间:
2017
期刊:
Int J Clin Exp Pathol
影响因子:
--
通讯作者:
Zheng-Jun Shang
Zheng-Jun Shang
中科院分区:
其他
文献类型:
--
作者:
Zhi Xu;Zhe Shao;Meng Wang;Jun-Fen Bai;Yong Song;Zheng-Jun Shang

文献摘要

相似文献

由于瞬时受体电位典范1(TRPC 1)与肿瘤生物学有关,本研究旨在研究TRPC 1在舌鳞状细胞癌(TSCC)中的表达,并评估肿瘤血管生成与临床预后的关系。在不同的细胞系中测量TRPC 1 mRNA和蛋白水平。采用免疫组化方法检测72例原发性TSCC和17例正常舌粘膜组织中TRPC 1蛋白的表达。分析TSCC中TRPC 1与临床病理参数的相关性,并计算微血管密度。结果显示,与正常对照组相比,TRPC 1在TSCC细胞系和组织标本中均显著过表达。TSCC中TRPC 1蛋白表达与EphA 2、ephrinA 1、e-NOS、VEGF-A表达及微血管密度显著相关。在TRPC 1高表达的患者中观察到不利的临床病理特征和结局。结果表明TRPC 1在一定程度上与TSCC的血管生成和恶性程度有关,提示TRPC 1是TSCC治疗的潜在靶点。
Since transient receptor potential canonical 1 (TRPC1) is involved in cancer biology, this study aimed .to investigate the expression of TRPC1 in tongue squamous cell carcinoma (TSCC) and to evaluate associations .between tumor angiogenesis and clinical outcomes. TRPC1 mRNA and protein levels were measured in different .cell lines. Immunohistochemical staining was conducted to detect TRPC1 protein expression in 72 primary TSCC .specimens and 17 specimens of normal tongue mucosa. The correlations among TRPC1 and clinicopathological .parameters were evaluated, and microvessel density was calculated in TSCC samples. Results demonstrated that.TRPC1 was significantly overexpressed in both TSCC cell lines and tissue samples, compared with normal control. In .addition, protein expression of TRPC1 was significantly correlated with EphA2, ephrinA1, e-NOS, VEGF-A expression .and microvessel density of TSCC specimens. Unfavorable clinicopathological features and outcomes were observed .in patients with high TRPC1 expression. Our results revealed that TRPC1 to certain extent is linked to angiogenesis .and malignity of TSCC, indicating TRPC1 is a potential target for TSCC treatment.